B type natriuretic peptide testing: where are we now?
Open Access
- 1 July 2004
- Vol. 90 (7) , 725-726
- https://doi.org/10.1136/hrt.2003.014787
Abstract
It is possible that plasma BNP measurement might be to heart failure what glycated haemoglobin measurement is to diabetes mellitus. Indeed, within 12–24 months, BNP testing might become a routine addition to the monitoring of patients with heart failure. In the meantime its main role is in helping to rule out heart failure in patients with new symptomsKeywords
This publication has 16 references indexed in Scilit:
- N-Terminal Pro-B–Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary SyndromesCirculation, 2002
- Plasma Natriuretic Peptides for Community Screening for Left Ventricular Hypertrophy and Systolic DysfunctionJAMA, 2002
- Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populationsBMJ, 2002
- BNP and congestive heart failureProgress in Cardiovascular Diseases, 2002
- The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2001
- Guidelines for the diagnosis and treatment of chronic heart failureEuropean Heart Journal, 2001
- Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care settingJournal of the American College of Cardiology, 2001
- A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot studyJournal of the American College of Cardiology, 2001
- Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: observational studyBMJ, 2000
- Biochemical detection of left-ventricular systolic dysfunctionThe Lancet, 1998